Patent application number | Description | Published |
20110217701 | Prognostic Marker for Endometrial Carcinoma - The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein. | 09-08-2011 |
20130267440 | MARKER FOR CARCINOMA - The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein. | 10-10-2013 |
20130338026 | Prognostic Marker for Endometrial Carcinoma - A method for diagnosis of different stages of endometrial cancer and for evaluating the probability of survival for an individual suffering from endometrial carcinoma, and for stratification of a therapy regimen for an endometrial tumor or monitoring therapeutic efficacy in an individual suffering considers the expression status of STMN1 gene or protein. A kit for use in the methods allows for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein. | 12-19-2013 |
20140200155 | Prognostic marker for endometrial carcinoma - The present invention relates to a method for diagnosing or determining the status of endometrial carcinoma in an individual afflicted with or suspected to be afflicted with endometrial carcinoma based on the phosphorylated stathmin compound whereby said stathmin is phosphorylated at position Serine 38. Moreover, the present invention relates to a method for evaluating the probability of survival, the clinical outcome or the treatment course of an individual afflicted with or suspected to be afflicted with endometrial carcinoma. In another aspect, the present invention relates to the stratification of the therapeutic regimen of an individual with endometrial carcinoma. In particular, the present invention provides a method for diagnosing or identifying endomentrial carcinoma with high grade aggressive phenotype, in particular, having low response and susceptibility to chemotherapeutic regimen, in particular, with respect to microtubule stabilization based regimen including treatment with taxanes. Moreover, the present invention relates to a kit for use in any of the above-referenced methods comprising means for determining the level or amount of phosphorylated pStathmin(S38) as well as assays for conducting the method according to the present invention. In one embodiment, the methods according to the present invention include the combined determination of stathmin and phosphorylated stathmin (pStathmin(S38)). | 07-17-2014 |